What is Knome?
Knome is a provider of bioinformatics infrastructure and insights, enabling researchers and clinicians to develop advanced next-generation sequencing (NGS) testing programs. The company's proprietary knoSYS platform offers a scalable informatics system designed for the analysis and interpretation of human genomic data. Furthermore, Knome's knomeDISCOVERY service provides comprehensive solutions tailored for pharmaceutical and academic researchers engaged in large-scale human exome and genome studies. The company's core mission is to equip its partners with innovative and efficient solutions to enhance pharmaceutical development success.
How much funding has Knome raised?
Knome has raised a total of $23.8M across 3 funding rounds:
Private Equity
$5M
Debt
$5.8M
Private Equity
$13M
Private Equity (2010): $5M, investors not publicly disclosed
Debt (2012): $5.8M, investors not publicly disclosed
Private Equity (2014): $13M, investors not publicly disclosed
What's next for Knome?
With a history of significant enterprise-level funding, Knome is well-positioned for continued growth and innovation in the rapidly evolving field of genomics. The recent strategic investment suggests a focus on expanding its platform capabilities, forging new partnerships within the pharmaceutical and research communities, and potentially scaling its operations to meet increasing market demand for sophisticated genomic data analysis tools. The company's trajectory indicates a commitment to empowering scientific discovery through advanced bioinformatics.
See full Knome company page
